Nuvilex (NASDAQ:PMCB) Issues Earnings Results

Nuvilex (NASDAQ:PMCB) announced its earnings results on Monday. The company reported ($0.54) earnings per share for the quarter, FiscalAI reports.

Nuvilex Stock Down 13.4%

Shares of PMCB stock traded down $0.06 during trading on Monday, reaching $0.39. The company’s stock had a trading volume of 579,385 shares, compared to its average volume of 181,622. The business has a fifty day moving average price of $0.57 and a 200-day moving average price of $0.68. The company has a market cap of $4.19 million, a price-to-earnings ratio of -0.13 and a beta of 0.66. Nuvilex has a one year low of $0.35 and a one year high of $1.51.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered Nuvilex from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 2nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Nuvilex has an average rating of “Sell”.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.